Molecular basis for broad neuraminidase immunity: Conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses

Journal of Virology

Volumn 87, Issue 16, 2013, Pages 9290-9300

  Wan, Hongquan ^a   Gao, Jin ^a   Xu, Kemin ^b,c   Chen, Hongjun ^b,c   Couzens, Laura K ^a   Rivers, Katie H ^a   Easterbrook, Judy D ^d   Yang, Kevin ^a   Zhong, Lei ^e   Rajabi, Mohsen ^a   Ye, Jianqiang ^f   Sultana, Ishrat ^a   Wan, Xiu Feng ^f   Liu, Xiufan ^e   Perez, Daniel R ^b,c   Taubenberger, Jeffery K ^d   Eichelberger, Maryna C ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e YANGZHOU UNIVERSITY   (China)

^f MISSISSIPPI STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY; SIALIDASE;

2009 H1N1 INFLUENZA; AMINO ACID ANALYSIS; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; CROSS REACTION; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MOUSE; MUTATION RATE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEASONAL INFLUENZA; VIRUS TITRATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CONSERVED SEQUENCE; CROSS PROTECTION; CROSS REACTIONS; EPITOPE MAPPING; EPITOPES, B-LYMPHOCYTE; IMMUNIZATION, PASSIVE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; MICE; MICE, INBRED BALB C; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS;

EID: 84881237033     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01203-13     Document Type: Article

References (47)

1. Palese P, Tobita K, Ueda M, Compans RW. 1974. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 61:397-410.
2. Lakdawala SS, Lamirande EW, Suguitan AL, Jr, Wang W, Santos CP, Vogel L, Matsuoka Y, Lindsley WG, Jin H, Subbarao K. 2011. Eurasianorigin gene segments contribute to the transmissibility, aerosol release, and morphology of the 2009 pandemic H1N1 influenza virus. PLoS Pathog. 7:e1002443. doi:10.1371/journal.ppat.1002443.
3. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. 2004. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J. Virol. 78:12665-12667.
4. Tong S, Li Y, Rivailler P, Conrardy C, Castillo DA, Chen LM, Recuenco S, Ellison JA, Davis CT, York IA, Turmelle AS, Moran D, Rogers S, Shi M, Tao Y, Weil MR, Tang K, Rowe LA, Sammons S, Xu X, Frace M, Lindblade KA, Cox NJ, Anderson LJ, Rupprecht CE, Donis RO. 2012. A distinct lineage of influenza A virus from bats. Proc. Natl. Acad. Sci. U. S. A. 109:4269-4274.
5. Pappas C, Aguilar PV, Basler CF, Solorzano A, Zeng H, Perrone LA, Palese P, Garcia-Sastre A, Katz JM, Tumpey TM. 2008. Single gene reassortants identify a critical role for PB1, HA, and NA in the high virulence of the 1918 pandemic influenza virus. Proc. Natl. Acad. Sci. U. S. A. 105:3064-3069.
6. Ma W, Liu Q, Bawa B, Qiao C, Qi W, Shen H, Chen Y, Ma J, Li X, Webby RJ, Garcia-Sastre A, Richt JA. 2012. The neuraminidase and matrix genes of the 2009 pandemic influenza H1N1 virus cooperate functionally to facilitate efficient replication and transmissibility in pigs. J. Gen. Virol. 93:1261-1268.
7. Ilyushina NA, Bovin NV, Webster RG. 2012. Decreased neuraminidase activity is important for the adaptation of H5N1 influenza virus to human airway epithelium. J. Virol. 86:4724-4733.
8. Kilbourne ED, Laver WG, Schulman JL, Webster RG. 1968. Antiviral activity of antiserum specific for an influenza virus neuraminidase. J. Virol. 2:281-288.
9. Clements ML, Betts RF, Tierney EL, Murphy BR. 1986. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J. Clin. Microbiol. 24:157-160.
10. Murphy BR, Kasel JA, Chanock RM. 1972. Association of serum antineuraminidase antibody with resistance to influenza in man. N. Engl. J. Med. 286:1329-1332.
11. Shoji Y, Chichester JA, Palmer GA, Farrance CE, Stevens R, Stewart M, Goldschmidt L, Deyde V, Gubareva L, Klimov A, Mett V, Yusibov V. 2011. An influenza N1 neuraminidase-specific monoclonal antibody with broad neuraminidase inhibition activity against H5N1 HPAI viruses. Hum. Vaccin. 7(Suppl):199-204.
12. Schulman JL, Khakpour M, Kilbourne ED. 1968. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J. Virol. 2:778-786.
13. Schulman JL, Kilbourne ED. 1969. The antigenic relationship of the neuraminidase of Hong Kong virus to that of other human strains of influenza A virus. Bull. World Health Organ. 41:425-428.
14. Chen Z, Kim L, Subbarao K, Jin H. 2012. The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets. Vaccine 30:2516-2522.
15. Marcelin G, DuBois R, Rubrum A, Russell CJ, McElhaney JE, Webby RJ. 2011. A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus. PLoS One 6:e26335. doi:10.1371/journal.pone.0026335.
16. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. 2007. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med. 4:e59. doi:10.1371/journal.pmed.0040059.
17. Easterbrook JD, Schwartzman LM, Gao J, Kash JC, Morens DM, Couzens L, Wan H, Eichelberger MC, Taubenberger JK. 2012. Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice. Virology 432:39-44.
18. Rockman S, Brown LE, Barr IG, Gilbertson B, Lowther S, Kachurin A, Kachurina O, Klippel J, Bodle J, Pearse M, Middleton D. 2013. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine. J. Virol. 87:3053-3061.
19. Gravel C, Li C, Wang J, Hashem AM, Jaentschke B, Xu KW, Lorbetskie B, Gingras G, Aubin Y, Van Domselaar G, Girard M, He R, Li X. 2010. Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences. Vaccine 28:5774-5784.
20. Air GM. 2012. Influenza neuraminidase. Influenza Other Respi. Viruses 6:245-256.
21. Air GM, Els MC, Brown LE, Laver WG, Webster RG. 1985. Location of antigenic sites on the three-dimensional structure of the influenza N2 virus neuraminidase. Virology 145:237-248.
22. Gulati U, Hwang CC, Venkatramani L, Gulati S, Stray SJ, Lee JT, Laver WG, Bochkarev A, Zlotnick A, Air GM. 2002. Antibody epitopes on the neuraminidase of a recent H3N2 influenza virus (A/Memphis/31/98). J. Virol. 76:12274-12280.
23. Webster RG, Brown LE, Laver WG. 1984. Antigenic and biological characterization of influenza virus neuraminidase (N2) with monoclonal antibodies. Virology 135:30-42.
24. Tulip WR, Varghese JN, Laver WG, Webster RG, Colman PM. 1992. Refined crystal structure of the influenza virus N9 neuraminidase-NC41 Fab complex. J. Mol. Biol. 227:122-148.
25. Venkatramani L, Bochkareva E, Lee JT, Gulati U, Graeme Laver W, Bochkarev A, Air GM. 2006. An epidemiologically significant epitope of a 1998 human influenza virus neuraminidase forms a highly hydrated interface in the NA-antibody complex. J. Mol. Biol. 356:651-663.
26. Colman PM, Varghese JN, Laver WG. 1983. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303:41-44.
27. Sandbulte MR, Westgeest KB, Gao J, Xu X, Klimov AI, Russell CA, Burke DF, Smith DJ, Fouchier RA, Eichelberger MC. 2011. Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. Proc. Natl. Acad. Sci. U. S. A. 108:20748-20753.
28. Higgins AD, Shaw CJ, Johnson JG, Navarro A, Chapman NA, Ewers SD, Stockwell JW, Carpenter JM, Olivo PD, Miao LY. 2010. Monoclonal antibody kit for identification of the novel 2009 H1N1 influenza A virus. J. Clin. Microbiol. 48:2677-2682.
29. Lambre CR, Terzidis H, Greffard A, Webster RG. 1990. Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates. J. Immunol. Methods 135:49-57.
30. Gerhard W, Webster RG. 1978. Antigenic drift in influenza A viruses. I. Selection and characterization of antigenic variants of A/PR/8/34 (HON1) influenza virus with monoclonal antibodies. J. Exp. Med. 148:383-392.
31. Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR. 2001. Universal primer set for the full-length amplification of all influenza A viruses. Arch. Virol. 146:2275-2289.
32. Boon AC, deBeauchamp J, Krauss S, Rubrum A, Webb AD, Webster RG, McElhaney J, Webby RJ. 2010. Cross-reactive neutralizing antibodies directed against pandemic H1N1 2009 virus are protective in a highly sensitive DBA/2 mouse influenza model. J. Virol. 84:7662-7667.
33. Li Q, Qi J, Zhang W, Vavricka CJ, Shi Y, Wei J, Feng E, Shen J, Chen J, Liu D, He J, Yan J, Liu H, Jiang H, Teng M, Li X, Gao GF. 2010. The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. Nat. Struct. Mol. Biol. 17:1266-1268.
34. Xu X, Zhu X, Dwek RA, Stevens J, Wilson IA. 2008. Structural characterization of the 1918 influenza virus H1N1 neuraminidase. J. Virol. 82: 10493-10501.
35. Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, Blackburn GM, Hay AJ, Gamblin SJ, Skehel JJ. 2006. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443:45-49.
36. Quan FS, Kim MC, Lee BJ, Song JM, Compans RW, Kang SM. 2012. Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection. Virology 430:127-135.
37. Couch RB, Kasel JA, Gerin JL, Schulman JL, Kilbourne ED. 1974. Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J. Infect. Dis. 129:411-420.
38. Beutner KR, Chow T, Rubi E, Strussenberg J, Clement J, Ogra PL. 1979. Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection. J. Infect. Dis. 140:844-850.
39. Ogra PL, Chow T, Beutner KR, Rubi E, Strussenberg J, DeMello S, Rizzone C. 1977. Clinical and immunologic evaluation of neuraminidasespecific influenza A virus vaccine in humans. J. Infect. Dis. 135:499-506.
40. Marcelin G, Bland HM, Negovetich NJ, Sandbulte MR, Ellebedy AH, Webb AD, Griffin YS, DeBeauchamp JL, McElhaney JE, Webby RJ. 2010. Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an agedependent manner. J. Infect. Dis. 202:1634-1638.
41. Johansson BE. 1999. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Vaccine 17:2073-2080.
42. Chen Z, Matsuo K, Asanuma H, Takahashi H, Iwasaki T, Suzuki Y, Aizawa C, Kurata T, Tamura S. 1999. Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutininand neuraminidase-expressing DNAs. Vaccine 17:653-659.
43. Bosch BJ, Bodewes R, de Vries RP, Kreijtz JH, Bartelink W, van Amerongen G, Rimmelzwaan GF, de Haan CA, Osterhaus AD, Rottier PJ. 2010. Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets. J. Virol. 84:10366-10374.
44. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA. 2009. Antibody recognition of a highly conserved influenza virus epitope. Science 324:246-251.
45. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox NJ, Bankston LA, Donis RO, Liddington RC, Marasco WA. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16:265-273.
46. Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, Ophorst C, Cox F, Korse HJ, Brandenburg B, Vogels R, Brakenhoff JP, Kompier R, Koldijk MH, Cornelissen LA, Poon LL, Peiris M, Koudstaal W, Wilson IA, Goudsmit J. 2011. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333:843-850.
47. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, Silacci C, FernandezRodriguez BM, Agatic G, Bianchi S, Giacchetto-Sasselli I, Calder L, Sallusto F, Collins P, Haire LF, Temperton N, Langedijk JP, Skehel JJ, Lanzavecchia A. 2011. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333:850-856.